Archive

EHA 2016: Professor Kwee Yong (London) and Dr Mark Cook (Birmingham) share EHA highlights that will affect practice in the UK, including excitement around daratumumab and where research in the molecular stratification of disease is guiding practice. Professor Sagar Lonial (Atlanta) shares his highlights of EHA and ASCO, including data confirming the benefit of maintenance therapy and of transplant, and Professor Roman Hajek (Ostrava) gives a reality check on what the new data means for patients and haematolgists.

Pioglitazone shows efficacy against a chronic liver disease

by Bruce Sylvester: Pioglitazone shows efficacy against the progression of nonalcoholic steatohepatitis, or NASH, a chronic liver disease caused by a buildup of fat. Researchers reported this finding… read more.

Single paediatric anesthesia entails no apparent cognitive risks

by Bruce Sylvester: A single exposure to general anesthesia does not lead to a cognitive risk in healthy children under age three, researchers reported On June 7, 2016… read more.

ASCO 2016: Previously untreatable advanced bladder cancer patients respond to immunotherapy

by Bruce Sylvester: Anti-PD-L1 immunotherapy atezolizumab (TECENTRIQ) has shown efficacy in previously untreated patients with advanced bladder cancer who are ineligible for standard treatment with cisplatin.

ILTS 2016 Report: Once-daily tacrolimus sees favourable results worldwide

by Thomas R. Collins: Leading transplant experts say they’ve had a good experience using the once-a-day tacrolimus regimen, reporting better patient adherence compared to the twice-a-day version, along… read more.

ISH/BSH 2016: DLBCL: controversies and global challenges

Dr Sridhar Chaganti, University Hospital, Birmingham NHS Foundation Trust, UK. by Christine Clark: In general the outcomes of treatment for diffuse large B-cell lymphoma (DLBCL) are good –… read more.

ISH/BSH 2016: Changing treatment paradigms in multiple relapse HL

Professor Karl Peggs, University College, London. by Christine Clark: There are numerous regimens for salvage treatment of Hodgkin lymphoma and all are associated with an overall response rate… read more.

ISH/BSH 2016: Professor John Radford (The University of Manchester) and Dr Graham Collins (Oxford University Hospitals) discuss the key issues to come out of the session on challenging current clinical practices in HL. Also included associated article entitled 'Rethinking risk for better outcomes in ASCT'

Rethinking risk for better outcomes in ASCT by Christine Clark Dr Craig Moskowitz, Memorial Sloan Kettering Cancer Center, NY, USA. Patient populations are changing – before 2010 all… read more.

ISH/BSH 2016: Dr Craig Moskowitz (Memorial Sloan Kettering Cancer Center, NY, USA) and Professor David Linch (University College London Hospital) discuss the role of transplant in HL. Also included an associated article entitled ‘Allogeneic stem cell transplantation: still a role in CLL/lymphoma?’

Allogeneic stem cell transplantation: still a role in CLL/lymphoma? by Christine Clark Professor Peter Dreger, Heidelberg University Hospital, Germany. The goal of allogeneic transplant therapy is to provide… read more.

ISH/BSH 2016: Professor Keith Stewart (Mayo Clinic, USA) discusses current dilemmas in MM, not least of which is how to manage patients with the ever growing number of new agents. He discusses the Mayo Clinic algorithm, whilst Professor Paul G. Richardson (Dana-Farber, USA) discusses the Dana-Farber algorithm for managing MM

ISH/BSH 2016 Abstracts and Posters: Results from the NCRI Myeloma XI trial

Charlotte Pawlyn and John R Jones (both of Institute of Cancer Research, London) and Ruth de Tute, St James’s University Hospital, Leeds. by Maria Dalby: Quadruplet therapy with… read more.

ISH/BSH 2016: Professor Philippe Moreau from Nantes in France reviewed the rationale for the new diagnostic criteria and highlighted the gaps in current risk models for stratifying the risk of progression to MM… Also included article entitled ‘High-risk smouldering myeloma’

High-risk smouldering myeloma by Maria Dalby Professor Philippe Moreau, University Hospital Hôtel-Dieu, Nantes, France Subsequent to the publication of updated diagnostic criteria for MM in 2014,1 MM clinicians have… read more.